Pfizer Aktie News

Bristol Myers Squibb has a high dividend yield, is very cheap, and may have better growth prospects than it might seem at first glance. Pfizer now has a 7% yield, and may have found a solution to its patent cliff issue.

These two tried-and-tested healthcare giants have compelling portfolios and pipelines. Pfizer is moving on from the pandemic era, and a stream of acquisitions has bolstered its pipeline.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Informati...

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).

Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028.

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.

Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.

Pfizer's sales and profits came in better than expected for the third quarter. The stock, however, remains down for the year.